Host-microbe interactions in the pathogenesis of invasive group a streptococcal infections

Journal of Medical Microbiology

Volumn 49, Issue 10, 2000, Pages 849-852

  Norrby Teglund, A ^a   Kotb, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; M PROTEIN; METALLOPROTEINASE; REGULATOR PROTEIN; SUPERANTIGEN; VIRULENCE FACTOR;

BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; EDITORIAL; ENZYME ACTIVITY; HOST RESISTANCE; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SORE THROAT; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME;

EID: 0033808289     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-49-10-849     Document Type: Editorial

References (34)

1. Streptococcal M protein: Molecular design and biological behavior
2. Variation of multifunctional surface binding proteins - A virulence strategy for group A streptococci?
3. Human kininogens interact with M protein, a bacterial surface protein and virulence determinant
4. Absorption of kininogen from human plasma by Streptococcus pyogenes is followed by the release of bradykinin
5. Streptococcal cysteine proteinase releases kinins: A novel virulence mechanism
6. Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease
7. A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin
8. Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes
9. Risk factors in the pathogenesis of invasive group A streptococcal infections: Role of protective humoral immunity
10. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease
11. Streptococcal cysteine protease augments lung injury induced by products of group A streptococci
12. Vaccination with streptococcal extracellular cysteine protease (interleukin-I beta convertase) protects mice against challenge with heterologous group A streptococci
13. Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains
14. Extracellular cysteine protease produced by Streptococcus pyogenes participates in the pathogenesis of invasive skin infection and dissemination in mice
15. Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs
16. Role of streptococcal pyrogenic exotoxin B in the mouse model of group A streptococcal infection
17. Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection
18. Protein GRAB of Streptococcus pyogenes regulates proteolysis at the bacterial surface by binding alpha2-macroglobulin
19. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function
20. Hypervariability generated by natural selection in an extracellular complement-inhibiting protein of serotype M1 strains of group A streptococcus
21. Rapid selection of complement-inhibiting protein variants in group A Streptococcus epidemic waves
22. Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and non-severe invasive disease
23. Nonpolar inactivation of the hypervariable streptococcal inhibitor of complement gene (sic) in serotype M1 Streptococcus pyogenes significantly decreases mouse mucosal colonization
24. Bacterial pyrogenic exotoxins as superantigens
25. Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project
26. Preferential stimulation of human lymphocytes by oligodeoxynucleotides that copy DNA CpG motifs present in virulent genes of group A streptococci
27. Aspects of the pathogenesis of serious group A streptococcal infections in Sweden 1988-1989
28. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome
29. HLA class II alleles associated with outcome of invasive group A streptococcal infection
30. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens
31. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production
32. Opsonic antibodies to the surface M protein of group A streptococci, in pooled normal immunoglobulins (IVIG): Potential impact on the clinical efficacy of IVIG therapy in severe invasive group A streptococcal infections
33. Novel therapies in streptococcal toxic shock syndrome: Attenuation of virulence factor expression and modulation of the host response
34. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - A comparative observational study